Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.74 |
| ▸ | LMNA | P02545 | 1/20 | 0.74 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.74 |
| ▸ | FAAH | O00519 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 3/20 | 0.48 |
| ▸ | NAAA | Q02083 | 1/20 | 0.48 |
| ▸ | DGKA | P23743 | 1/20 | 0.48 |
| ▸ | CES2 | O00748 | 4/20 | 0.46 |
| ▸ | CES1 | P23141 | 3/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dodecane SCHEMBL3308504 | 1.00 | ALDH1A1 (0.74) | ALDH1A1LMNAHSD17B10FAAHMEN1 | |
| Heptane SCHEMBL2399914 | 1.00 | ALDH1A1 (0.74) | ALDH1A1LMNAHSD17B10FAAHMEN1 | |
| Heptane SCHEMBL1614041 | 1.00 | ALDH1A1 (0.74) | ALDH1A1LMNAHSD17B10FAAHMEN1 | |
| Dodecane SCHEMBL1747351 | 1.00 | ALDH1A1 (0.74) | ALDH1A1LMNAHSD17B10FAAHMEN1 | |
| Heptane SCHEMBL9107982 | 1.00 | ALDH1A1 (0.74) | ALDH1A1LMNAHSD17B10FAAHMEN1 | |
| Heptane SCHEMBL11904142 | 1.00 | ALDH1A1 (0.74) | ALDH1A1LMNAHSD17B10FAAHMEN1 | |
| Heptane SCHEMBL276236 | 1.00 | ALDH1A1 (0.74) | ALDH1A1LMNAHSD17B10FAAHMEN1 | |
| Heptane SCHEMBL1680974 | 1.00 | ALDH1A1 (0.74) | ALDH1A1LMNAHSD17B10FAAHMEN1 | |
| Hexadecane SCHEMBL3291441 | 1.00 | ALDH1A1 (0.74) | ALDH1A1LMNAHSD17B10FAAHMEN1 | |
| Heptane SCHEMBL18725336 | 1.00 | ALDH1A1 (0.74) | ALDH1A1LMNAHSD17B10FAAHMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3778573-B1 | COMPOUND WITH ANTICANCER ACTIVITY | KYOWA KIRIN CO LTD (JP) | 2024-04-24 | — | — | EP | disclosed |
| CN-111936468-B | Compounds with anticancer activity | 协和麒麟株式会社 | 2024-03-08 | — | — | CN | disclosed |
| EP-3283642-B1 | PROGNOSTIC BIOMARKERS FOR TTK INHIBITOR CHEMOTHERAPY | NETHERLANDS TRANSLATIONAL RES CENTER HOLDING B V (NL) | 2023-10-11 | — | — | EP | disclosed |
| US-20230159554-A1 | COMPOUND WITH ANTICANCER ACTIVITY | KYOWA KIRIN CO., LTD. (JP) | 2023-05-25 | — | — | US | disclosed |
| US-11629152-B2 | Compound with anticancer activity | KYOWA KIRIN CO., LTD. (JP) | 2023-04-18 | — | — | US | disclosed |
| US-11591344-B2 | — | — | 2023-02-28 | — | — | US | disclosed |
| CN-114502534-A | BET degradant | 协和麒麟株式会社 | 2022-05-13 | — | — | CN | disclosed |
| US-20220056540-A1 | PROGNOSTIC BIOMARKERS FOR TTK INHIBITOR CHEMOTHERAPY | NETHERLANDS TRANSLATIONAL RESEARCH CENTER B.V. (NL) | 2022-02-24 | — | — | US | disclosed |
| US-11208696-B2 | Prognostic biomarkers for TTK inhibitor chemotherapy | NETHERLANDS TRANSLATIONAL RESEARCH CENTER B.V. (NL) | 2021-12-28 | — | — | US | disclosed |
| EP-3778573-A1 | COMPOUND WITH ANTICANCER ACTIVITY | Kyowa Kirin Co., Ltd. (JP) | 2021-02-17 | — | — | EP | disclosed |
| US-6410684-B1 | ENZYME INHIBITOR FOR USE IN THE TREATMENT OF THROMBOSIS | AKZO NOBEL N.V. (NL) | 2002-06-25 | — | — | US | disclosed |
| EP-0956293-A1 | THROMBIN INHIBITORS | Akzo Nobel N.V. (NL) | 1999-11-17 | — | — | EP | disclosed |
| CN-1212705-A | Serine protease inhibitors | AKZO NOBEL NV (NL) | 1999-03-31 | — | — | CN | disclosed |
| CN-1212704-A | Serine protease inhibitors | AKZO NOBEL NV (NL) | 1999-03-31 | — | — | CN | disclosed |
| EP-0886647-A1 | SERINE PROTEASE INHIBITORS | Akzo Nobel N.V. (NL) | 1998-12-30 | — | — | EP | disclosed |
| WO-1998007308-A2 | THROMBIN INHIBITORS | AKZO NOBEL N.V. (NL) | 1998-02-26 | — | — | WO | disclosed |
| WO-1997031937-A1 | SERINE PROTEASE INHIBITORS | AKZO NOBEL N.V. (NL) | 1997-09-04 | — | — | WO | disclosed |
| CN-1128990-A | N-substituted azaheterocyclic carboxylic acids and esters thereof | NOVO NORDISK AS (DK) | 1996-08-14 | — | — | CN | disclosed |
| EP-0705246-A1 | N-SUBSTITUTED AZAHETEROCYCLIC CARBOXYLIC ACIDS AND ESTERS THEREOF | NOVO NORDISK A/S (DK) | 1996-04-10 | — | — | EP | disclosed |
| WO-1995000483-A1 | N-SUBSTITUTED AZAHETEROCYCLIC CARBOXYLIC ACIDS AND ESTERS THEREOF | NOVO NORDISK A/S (DK) | 1995-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220056540-A1 | PROGNOSTIC BIOMARKERS FOR TTK INHIBITOR CHEMOTHERAPY | TTBK1, CTNNB1, TTK | ALDH1A1 2286/4885LMNA 1795/4885HSD17B10 1521/4885 |
| US-20230159554-A1 | COMPOUND WITH ANTICANCER ACTIVITY | TP53, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, RCC2 | ALDH1A1 199/4885LMNA 1695/4885HSD17B10 2015/4885 |
| US-11591344-B2 | — | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, RCC2, TP53 | ALDH1A1 84/4885LMNA 2141/4885HSD17B10 1134/4885 |
| US-11208696-B2 | Prognostic biomarkers for TTK inhibitor chemotherapy | TTBK1, CTNNB1, TTK | ALDH1A1 2286/4885LMNA 1795/4885HSD17B10 1521/4885 |
| US-11629152-B2 | Compound with anticancer activity | TP53, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, RCC2 | ALDH1A1 199/4885LMNA 1695/4885HSD17B10 2015/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.